includes functional

training, adaptations, and Luminespib adequate analgesia as suggested in Table 1–5. (Level 2) [ [15, 45] ] COX-2 inhibitors have a greater role in this situation. (Level 2) [ [46, 47] ] Other NSAIDs should be avoided. (Level 2) [ [48] ] When pain is disabling, orthopedic surgery may be indicated. (Level 5) [ [49] ] Patients with persisting pain should be referred to a specialized pain management team. Surgery may be required for hemophilia-related complications or unrelated diseases. The following issues are of prime importance when performing surgery on persons with hemophilia: Surgery for patients with hemophilia will require additional planning and interaction with the healthcare team than what is required for other patients. A hemophilia patient

requiring surgery is best managed at or in consultation with a comprehensive hemophilia treatment center. (Level 3) [ [50, 51] ] The anesthesiologist should have experience treating patients with bleeding disorders. Adequate laboratory support is required for reliable monitoring of clotting factor level and inhibitor testing. Preoperative assessment should include inhibitor screening and inhibitor assay, particularly if the recovery of the replaced factor is significantly less than expected. (Level 4) [ [52, Ferrostatin-1 order 53] ] Surgery should be scheduled early in the week and early in the day for optimal laboratory and blood bank support, if needed. Adequate quantities of clotting factor concentrates should be available for the surgery itself and to maintain adequate coverage postoperatively for the length of time required MCE for healing and/or rehabilitation. If clotting factor concentrates are not available, adequate blood bank support for plasma components is needed. The dosage and duration of clotting factor concentrate coverage depend on the type of surgery performed (Tables 7-1, 7-2). Effectiveness of

hemostasis for surgical procedures may be judged as per criteria defined by the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (Table 1–6). Patients with mild hemophilia A, as well as patients receiving intensive factor replacement for the first time, are at particular risk of inhibitor development and should be re-screened 4–12 weeks postoperatively. (Level 4) [ [54] ] Careful monitoring for inihibitors is also advisable in patients with non-severe hemophilia A receiving continuous infusion after surgery [55]. Infusion of factor concentrates/hemostatic agents is necessary before invasive diagnostic procedures such as lumbar puncture, arterial blood gas determination, or any endoscopy with biopsy. Intra-operative and postoperative blood loss similar (within 10%) to the non-hemophilic patient.